BASF's new bioactive ingredient the wellness elixir for healthy skin
The active ingredient is a 100% natural extract from the chaga mushroom, obtained using an innovative eco-friendly technology: subcritical water extraction.
Extracted from the chaga mushroom (Inonotus obliquus), native to the Northern Canadian forest, Inolixir is the most recent addition to BASF’s portfolio of bioactive ingredients. With its antioxidant and anti-inflammatory properties, it fortifies the skin’s natural protection system by strengthening barrier function and the microvascular network – working on all fronts to return skin to a healthier condition, with visible results on fine lines, dark-circles and redness.
A superfood ingredient for healthy skin
The chaga mushroom is a superfood renowned for various health benefits and has both traditional and modern uses. With Inolixir (INCI: Glycerin (and) Water (and) Inonotus Obliquus (Mushroom) Extract), BASF scientists have now harnessed the chaga mushroom’s power for use in skin care products, catering to the worldwide consumer trend of changing perceptions of beauty and the increasing popularity of a more holistic approach. This often involves consumers making lifestyle changes and, importantly, looking for cosmetic products with natural ingredients.
A powerful, dual action bioactive ingredient offering quick and long-lasting results
Inolixir works in two ways: first, it offers a wellness approach proven to be effective on tired and stressed skin. Study participants reported that Inolixir was as effective as a 5-day relaxation cure in mitigating fatigue lines, dark circles and dullness. Second, the bioactive ingredient presents dermocosmetic solutions for sensitive skin: it offers anti-redness and anti-dullness benefits, leading 85% of study participants to perceive a health benefit for their skin and 91% to report increased skin comfort within 7 to 28 days of application.
Inolixir is a hyper-concentrated bioactive ingredient, benefitting from all the nutrients and properties of the chaga mushroom thanks to an innovative and eco-friendly technology: subcritical water extraction (SWE). Instead of organic solvents, this method uses pressurized water heated to between 100 °C and 374 °C for extraction. In vitro tests have proven that SWE extracts phytochemicals more efficiently than other common methods, such as conventional hydroethanolic extraction and water extraction.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.